futibatinib (Lytgobi) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Breakthrough Therapy FDA Accelerated Approval FDA Priority Review FDA
AACT PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: C=CC(=O)N1CC[C@H](n2nc(C#Cc3cc(OC)cc(OC)c3)c3c(N)ncnc32)C1
  • InChIKey: KEIPNCCJPRMIAX-HNNXBMFYSA-N
  • Mol. Mass: 418.46
  • ALogP: 1.78
  • ChEMBL Molecule:
    futibatinib  
More Chemistry

Pharmacology

Alternative names

tas-120

Organizations (11)

Research & Development (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (1)


 

Cholangiocarcinoma (approved 2022)

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Breast Neoplasms (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Cholangiocarcinoma (Phase 3)

Endometrial Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Gene Rearrangement (Phase 2)

Leukemia, Myeloid (Phase 2)

Mutation (Phase 1/Phase 2)

Neoplasm Metastasis (Phase 1/Phase 2)

Neoplasms (Phase 2)

Receptors, Fibroblast Growth Factor (Phase 3)

Sarcoma (Phase 3)

Stomach Neoplasms (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial Organizations: 10

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue